Inclusion Criteria:

- Signed written informed consent must be obtained and documented according to ICH GCP,
the local regulatory requirements, and permission to use private health information
in accordance with HIPPA prior to study-specific screening procedures

- A histologically or cytologically confirmed RCC or other c-Met expression tumors that
is metastatic

- Patient must have available archival tumor tissue or accessible tumor that is safely
amenable to tumor biopsy

- ≥ 18 years of age

- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors

- Karnofsky performance status ≥ 70%

- Male or female patients of child-producing potential must agree to use contraception
or avoidance of pregnancy measures during the study and for 30 days after the last
ARQ 197 dose

- Females of childbearing potential must have a negative serum pregnancy test

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of
normal (ULN) or ≤ 5.0 × ULN with metastatic liver disease.

- Hemoglobin (Hgb) ≥ 10 g/dl

- Total bilirubin ≤ 1.5 × ULN

- Creatinine ≤ 1.5 x ULN

- Absolute neutrophil count ≥ 1.5 x 10^9/L

- Platelets ≥ 100 x 10^9/L

Exclusion Criteria:

- Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
within four weeks of first dose

- Surgery within 4 weeks prior to first dose

- Known brain metastases

- Pregnant or breastfeeding

- Significant gastrointestinal disorder(s), in the opinion of the Principal
Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric
resection)

- Unable or unwilling to swallow ARQ 197 capsules twice daily

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, clinically significant non-healing or healing wounds, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant
pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled
infection or psychiatric illness/social situations that would limit compliance with
study requirements

- Bradycardia at baseline or known history of arrhythmia